[Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery enhances late toxicities].
Identifieur interne : 000489 ( France/Analysis ); précédent : 000488; suivant : 000490[Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery enhances late toxicities].
Auteurs : A. Toledano [France] ; P. Garaud ; D. Serin ; A. Fourquet ; J-F Bosset ; J. Miny-Buffet ; A. Favre ; D. Azria ; G. Body ; O. Le Floch ; G. CalaisSource :
- Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [ 1278-3218 ] ; 2006.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antinéoplasiques (administration et posologie), Antinéoplasiques alcoylants (administration et posologie), Atrophie, Cyclophosphamide (administration et posologie), Femelle, Fibrose, Fractionnement de la dose d'irradiation, Humains, Lymphadénectomie, Mastectomie partielle, Mitoxantrone (administration et posologie), Méthode en simple aveugle, Pigmentation de la peau (), Pigmentation de la peau (effets des radiations), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Radiothérapie adjuvante (effets indésirables), Région mammaire (), Région mammaire (effets des radiations), Sujet âgé, Traitement médicamenteux adjuvant (effets indésirables), Tumeurs du sein (), Tumeurs du sein (radiothérapie), Tumeurs du sein (traitement médicamenteux), Télangiectasie (), Télangiectasie (étiologie), Études de suivi, Études prospectives.
- MESH :
- administration et posologie : Antinéoplasiques, Antinéoplasiques alcoylants, Cyclophosphamide, Mitoxantrone.
- effets des radiations : Pigmentation de la peau, Région mammaire.
- effets indésirables : Radiothérapie adjuvante, Traitement médicamenteux adjuvant.
- radiothérapie : Tumeurs du sein.
- traitement médicamenteux : Tumeurs du sein.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- étiologie : Télangiectasie.
- Adulte, Adulte d'âge moyen, Atrophie, Femelle, Fibrose, Fractionnement de la dose d'irradiation, Humains, Lymphadénectomie, Mastectomie partielle, Méthode en simple aveugle, Pigmentation de la peau, Région mammaire, Sujet âgé, Tumeurs du sein, Télangiectasie, Études de suivi, Études prospectives.
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Agents (administration & dosage), Antineoplastic Agents, Alkylating (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Atrophy, Breast (drug effects), Breast (radiation effects), Breast Neoplasms (drug therapy), Breast Neoplasms (radiotherapy), Breast Neoplasms (surgery), Chemotherapy, Adjuvant (adverse effects), Cyclophosphamide (administration & dosage), Dose Fractionation, Female, Fibrosis, Follow-Up Studies, Humans, Lymph Node Excision, Mastectomy, Segmental, Middle Aged, Mitoxantrone (administration & dosage), Prospective Studies, Radiotherapy, Adjuvant (adverse effects), Single-Blind Method, Skin Pigmentation (drug effects), Skin Pigmentation (radiation effects), Telangiectasis (chemically induced), Telangiectasis (etiology).
- MESH :
- chemical , administration & dosage : Antineoplastic Agents, Antineoplastic Agents, Alkylating, Cyclophosphamide, Mitoxantrone.
- adverse effects : Chemotherapy, Adjuvant, Radiotherapy, Adjuvant.
- chemically induced : Telangiectasis.
- drug effects : Breast, Skin Pigmentation.
- drug therapy : Breast Neoplasms.
- etiology : Telangiectasis.
- radiation effects : Breast, Skin Pigmentation.
- radiotherapy : Breast Neoplasms.
- surgery : Breast Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Atrophy, Dose Fractionation, Female, Fibrosis, Follow-Up Studies, Humans, Lymph Node Excision, Mastectomy, Segmental, Middle Aged, Prospective Studies, Single-Blind Method.
Abstract
In 1996, a multicenter randomized study comparing after breast-conservative surgery, sequential vs concurrent adjuvant chemotherapy (CT) with radiation therapy (RT) was initiated (ARCOSEIN study). Seven hundred sixteen patients were included in this trial. After a median follow-up of 6.7 (4.3-9) years, we decided to prospectively evaluate the late effects of these two strategies.
DOI: 10.1016/j.canrad.2006.03.001
PubMed: 16632399
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003A20
- to stream PubMed, to step Curation: 003A20
- to stream PubMed, to step Checkpoint: 003A20
- to stream Ncbi, to step Merge: 002201
- to stream Ncbi, to step Curation: 002201
- to stream Ncbi, to step Checkpoint: 002201
- to stream Main, to step Merge: 007952
- to stream Main, to step Curation: 007785
- to stream Main, to step Exploration: 007785
- to stream France, to step Extraction: 000489
Links to Exploration step
pubmed:16632399Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery enhances late toxicities].</title>
<author><name sortKey="Toledano, A" sort="Toledano, A" uniqKey="Toledano A" first="A" last="Toledano">A. Toledano</name>
<affiliation wicri:level="3"><nlm:affiliation>Service d'Oncologie-Radiothérapie, Hôpital Tenon, APHP, Paris, France. alain.toledano@gmail.com</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'Oncologie-Radiothérapie, Hôpital Tenon, APHP, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garaud, P" sort="Garaud, P" uniqKey="Garaud P" first="P" last="Garaud">P. Garaud</name>
</author>
<author><name sortKey="Serin, D" sort="Serin, D" uniqKey="Serin D" first="D" last="Serin">D. Serin</name>
</author>
<author><name sortKey="Fourquet, A" sort="Fourquet, A" uniqKey="Fourquet A" first="A" last="Fourquet">A. Fourquet</name>
</author>
<author><name sortKey="Bosset, J F" sort="Bosset, J F" uniqKey="Bosset J" first="J-F" last="Bosset">J-F Bosset</name>
</author>
<author><name sortKey="Miny Buffet, J" sort="Miny Buffet, J" uniqKey="Miny Buffet J" first="J" last="Miny-Buffet">J. Miny-Buffet</name>
</author>
<author><name sortKey="Favre, A" sort="Favre, A" uniqKey="Favre A" first="A" last="Favre">A. Favre</name>
</author>
<author><name sortKey="Azria, D" sort="Azria, D" uniqKey="Azria D" first="D" last="Azria">D. Azria</name>
</author>
<author><name sortKey="Body, G" sort="Body, G" uniqKey="Body G" first="G" last="Body">G. Body</name>
</author>
<author><name sortKey="Le Floch, O" sort="Le Floch, O" uniqKey="Le Floch O" first="O" last="Le Floch">O. Le Floch</name>
</author>
<author><name sortKey="Calais, G" sort="Calais, G" uniqKey="Calais G" first="G" last="Calais">G. Calais</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16632399</idno>
<idno type="pmid">16632399</idno>
<idno type="doi">10.1016/j.canrad.2006.03.001</idno>
<idno type="wicri:Area/PubMed/Corpus">003A20</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003A20</idno>
<idno type="wicri:Area/PubMed/Curation">003A20</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003A20</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003A20</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003A20</idno>
<idno type="wicri:Area/Ncbi/Merge">002201</idno>
<idno type="wicri:Area/Ncbi/Curation">002201</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002201</idno>
<idno type="wicri:doubleKey">1278-3218:2006:Toledano A:concurrent:administration:of</idno>
<idno type="wicri:Area/Main/Merge">007952</idno>
<idno type="wicri:Area/Main/Curation">007785</idno>
<idno type="wicri:Area/Main/Exploration">007785</idno>
<idno type="wicri:Area/France/Extraction">000489</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery enhances late toxicities].</title>
<author><name sortKey="Toledano, A" sort="Toledano, A" uniqKey="Toledano A" first="A" last="Toledano">A. Toledano</name>
<affiliation wicri:level="3"><nlm:affiliation>Service d'Oncologie-Radiothérapie, Hôpital Tenon, APHP, Paris, France. alain.toledano@gmail.com</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'Oncologie-Radiothérapie, Hôpital Tenon, APHP, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garaud, P" sort="Garaud, P" uniqKey="Garaud P" first="P" last="Garaud">P. Garaud</name>
</author>
<author><name sortKey="Serin, D" sort="Serin, D" uniqKey="Serin D" first="D" last="Serin">D. Serin</name>
</author>
<author><name sortKey="Fourquet, A" sort="Fourquet, A" uniqKey="Fourquet A" first="A" last="Fourquet">A. Fourquet</name>
</author>
<author><name sortKey="Bosset, J F" sort="Bosset, J F" uniqKey="Bosset J" first="J-F" last="Bosset">J-F Bosset</name>
</author>
<author><name sortKey="Miny Buffet, J" sort="Miny Buffet, J" uniqKey="Miny Buffet J" first="J" last="Miny-Buffet">J. Miny-Buffet</name>
</author>
<author><name sortKey="Favre, A" sort="Favre, A" uniqKey="Favre A" first="A" last="Favre">A. Favre</name>
</author>
<author><name sortKey="Azria, D" sort="Azria, D" uniqKey="Azria D" first="D" last="Azria">D. Azria</name>
</author>
<author><name sortKey="Body, G" sort="Body, G" uniqKey="Body G" first="G" last="Body">G. Body</name>
</author>
<author><name sortKey="Le Floch, O" sort="Le Floch, O" uniqKey="Le Floch O" first="O" last="Le Floch">O. Le Floch</name>
</author>
<author><name sortKey="Calais, G" sort="Calais, G" uniqKey="Calais G" first="G" last="Calais">G. Calais</name>
</author>
</analytic>
<series><title level="j">Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique</title>
<idno type="ISSN">1278-3218</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antineoplastic Agents (administration & dosage)</term>
<term>Antineoplastic Agents, Alkylating (administration & dosage)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Atrophy</term>
<term>Breast (drug effects)</term>
<term>Breast (radiation effects)</term>
<term>Breast Neoplasms (drug therapy)</term>
<term>Breast Neoplasms (radiotherapy)</term>
<term>Breast Neoplasms (surgery)</term>
<term>Chemotherapy, Adjuvant (adverse effects)</term>
<term>Cyclophosphamide (administration & dosage)</term>
<term>Dose Fractionation</term>
<term>Female</term>
<term>Fibrosis</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Lymph Node Excision</term>
<term>Mastectomy, Segmental</term>
<term>Middle Aged</term>
<term>Mitoxantrone (administration & dosage)</term>
<term>Prospective Studies</term>
<term>Radiotherapy, Adjuvant (adverse effects)</term>
<term>Single-Blind Method</term>
<term>Skin Pigmentation (drug effects)</term>
<term>Skin Pigmentation (radiation effects)</term>
<term>Telangiectasis (chemically induced)</term>
<term>Telangiectasis (etiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Antinéoplasiques (administration et posologie)</term>
<term>Antinéoplasiques alcoylants (administration et posologie)</term>
<term>Atrophie</term>
<term>Cyclophosphamide (administration et posologie)</term>
<term>Femelle</term>
<term>Fibrose</term>
<term>Fractionnement de la dose d'irradiation</term>
<term>Humains</term>
<term>Lymphadénectomie</term>
<term>Mastectomie partielle</term>
<term>Mitoxantrone (administration et posologie)</term>
<term>Méthode en simple aveugle</term>
<term>Pigmentation de la peau ()</term>
<term>Pigmentation de la peau (effets des radiations)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Radiothérapie adjuvante (effets indésirables)</term>
<term>Région mammaire ()</term>
<term>Région mammaire (effets des radiations)</term>
<term>Sujet âgé</term>
<term>Traitement médicamenteux adjuvant (effets indésirables)</term>
<term>Tumeurs du sein ()</term>
<term>Tumeurs du sein (radiothérapie)</term>
<term>Tumeurs du sein (traitement médicamenteux)</term>
<term>Télangiectasie ()</term>
<term>Télangiectasie (étiologie)</term>
<term>Études de suivi</term>
<term>Études prospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Antineoplastic Agents, Alkylating</term>
<term>Cyclophosphamide</term>
<term>Mitoxantrone</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Antinéoplasiques alcoylants</term>
<term>Cyclophosphamide</term>
<term>Mitoxantrone</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Chemotherapy, Adjuvant</term>
<term>Radiotherapy, Adjuvant</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Telangiectasis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Breast</term>
<term>Skin Pigmentation</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des radiations" xml:lang="fr"><term>Pigmentation de la peau</term>
<term>Région mammaire</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Radiothérapie adjuvante</term>
<term>Traitement médicamenteux adjuvant</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Telangiectasis</term>
</keywords>
<keywords scheme="MESH" qualifier="radiation effects" xml:lang="en"><term>Breast</term>
<term>Skin Pigmentation</term>
</keywords>
<keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Télangiectasie</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Atrophy</term>
<term>Dose Fractionation</term>
<term>Female</term>
<term>Fibrosis</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Lymph Node Excision</term>
<term>Mastectomy, Segmental</term>
<term>Middle Aged</term>
<term>Prospective Studies</term>
<term>Single-Blind Method</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Atrophie</term>
<term>Femelle</term>
<term>Fibrose</term>
<term>Fractionnement de la dose d'irradiation</term>
<term>Humains</term>
<term>Lymphadénectomie</term>
<term>Mastectomie partielle</term>
<term>Méthode en simple aveugle</term>
<term>Pigmentation de la peau</term>
<term>Région mammaire</term>
<term>Sujet âgé</term>
<term>Tumeurs du sein</term>
<term>Télangiectasie</term>
<term>Études de suivi</term>
<term>Études prospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In 1996, a multicenter randomized study comparing after breast-conservative surgery, sequential vs concurrent adjuvant chemotherapy (CT) with radiation therapy (RT) was initiated (ARCOSEIN study). Seven hundred sixteen patients were included in this trial. After a median follow-up of 6.7 (4.3-9) years, we decided to prospectively evaluate the late effects of these two strategies.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Azria, D" sort="Azria, D" uniqKey="Azria D" first="D" last="Azria">D. Azria</name>
<name sortKey="Body, G" sort="Body, G" uniqKey="Body G" first="G" last="Body">G. Body</name>
<name sortKey="Bosset, J F" sort="Bosset, J F" uniqKey="Bosset J" first="J-F" last="Bosset">J-F Bosset</name>
<name sortKey="Calais, G" sort="Calais, G" uniqKey="Calais G" first="G" last="Calais">G. Calais</name>
<name sortKey="Favre, A" sort="Favre, A" uniqKey="Favre A" first="A" last="Favre">A. Favre</name>
<name sortKey="Fourquet, A" sort="Fourquet, A" uniqKey="Fourquet A" first="A" last="Fourquet">A. Fourquet</name>
<name sortKey="Garaud, P" sort="Garaud, P" uniqKey="Garaud P" first="P" last="Garaud">P. Garaud</name>
<name sortKey="Le Floch, O" sort="Le Floch, O" uniqKey="Le Floch O" first="O" last="Le Floch">O. Le Floch</name>
<name sortKey="Miny Buffet, J" sort="Miny Buffet, J" uniqKey="Miny Buffet J" first="J" last="Miny-Buffet">J. Miny-Buffet</name>
<name sortKey="Serin, D" sort="Serin, D" uniqKey="Serin D" first="D" last="Serin">D. Serin</name>
</noCountry>
<country name="France"><region name="Île-de-France"><name sortKey="Toledano, A" sort="Toledano, A" uniqKey="Toledano A" first="A" last="Toledano">A. Toledano</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000489 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000489 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= France |étape= Analysis |type= RBID |clé= pubmed:16632399 |texte= [Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery enhances late toxicities]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i -Sk "pubmed:16632399" \ | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |